Aurinia Pharmaceuticals (AUPH) Misses Q2 EPS by 4c

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15).

For earnings history and earnings-related data on Aurinia Pharmaceuticals (AUPH) click here.

You May Also Be Interested In

• Activist investor presses Xerox to review financial services arm - Bloomberg
• UBS upgrades Lockheed Martin to Buy, sees 26% upside on missile growth
• Morgan Stanley Upgrades Lineage Inc (LINE) to Overweight